These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29132681)

  • 1. [DNA repair as a therapeutic target].
    Eberst L; Brahmi M; Cassier PA
    Bull Cancer; 2017 Nov; 104(11):988-998. PubMed ID: 29132681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impairment of DNA damage response and cancer].
    Rancoule C; Vallard A; Guy JB; Espenel S; Sauvaigo S; Rodriguez-Lafrasse C; Magné N
    Bull Cancer; 2017 Nov; 104(11):962-970. PubMed ID: 29132683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
    Sandhu SK; Yap TA; de Bono JS
    Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA Repair Proteins as Therapeutic Targets in Ovarian Cancer.
    López-Camarillo C; Rincón DG; Ruiz-García E; Astudillo-de la Vega H; Marchat LA
    Curr Protein Pept Sci; 2019; 20(4):316-323. PubMed ID: 30215333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
    Brown JS; O'Carrigan B; Jackson SP; Yap TA
    Cancer Discov; 2017 Jan; 7(1):20-37. PubMed ID: 28003236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCAness and prostate cancer: diagnostic and therapeutic considerations.
    Dhawan M; Ryan CJ
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):488-498. PubMed ID: 30131605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining and Modulating 'BRCAness'.
    Byrum AK; Vindigni A; Mosammaparast N
    Trends Cell Biol; 2019 Sep; 29(9):740-751. PubMed ID: 31362850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the DNA damage response in oncology: past, present and future perspectives.
    Basu B; Yap TA; Molife LR; de Bono JS
    Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
    Kruse V; Rottey S; De Backer O; Van Belle S; Cocquyt V; Denys H
    Acta Clin Belg; 2011; 66(1):2-9. PubMed ID: 21485757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibitors: Synthetic lethality in the clinic.
    Lord CJ; Ashworth A
    Science; 2017 Mar; 355(6330):1152-1158. PubMed ID: 28302823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging PARP inhibitors for treating breast cancer.
    Robert M; Patsouris A; Frenel JS; Gourmelon C; Augereau P; Campone M
    Expert Opin Emerg Drugs; 2018 Sep; 23(3):211-221. PubMed ID: 30251552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting DNA repair in breast cancer: a clinical and translational update.
    Amir E; Seruga B; Serrano R; Ocana A
    Cancer Treat Rev; 2010 Nov; 36(7):557-65. PubMed ID: 20385443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    Talens F; Jalving M; Gietema JA; Van Vugt MA
    Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
    Ivy SP; Kunos CA; Arnaldez FI; Kohn EC
    Expert Opin Investig Drugs; 2019 Sep; 28(9):771-785. PubMed ID: 31449760
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.